icon star paper   Hepatitis C Articles (HCV)  
Back grey_arrow_rt.gif
 
 
NIH Action plan for liver disease research
 
 
  News From NIH
 
Hepatology
Volume 40, Issue 6, December 2004
 
Jay H. Hoofnagle, M.D.
Liver Disease Research Branch NIDDK, National Institutes of Health Bethesda, MD
 
Note from Jules Levin: as you read through this notice & subsequently read the actual Plan you won't see mention of implementation or funding because funding this initiative is I believe a separate matter. I think we will have to weigh in with Congress & the Administration for adequate funding.
 
Article Text
 
The Liver Disease Research Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has recently led the development of a trans-NIH Action Plan for Liver Disease Research. The genesis of the Action Plan was a Congressional request asking for more focus for NIH-funded liver disease research. In response, the NIH created a Liver Disease Research Branch (LDRB) in the NIDDK and established a Liver Disease Subcommittee of the Digestive Diseases Interagency Coordinating Committee, a congressionally mandated committee responsible for coordination of digestive disease research activities among components of the NIH and other federal agencies. The Subcommittee, with significant leadership by the LDRB, was charged with creating a trans-NIH Action Plan for Liver Disease Research.
 
The Action Plan document will be published in December 2004. The Action Plan consists of 16 chapters on specific topic areas of liver disease research, as well as introductory and summary chapters. Each chapter was written by staff of the LDRB based on advice and input from a 5- to 8-person Working Group of research investigators, academicians, physicians, and concerned laypersons, as well as a representative from the Liver Disease Subcommittee. Each chapter includes an introductory and background section, a summary of recent advances, a central section describing important research goals in the future, and a final section describing steps to achieve the goals. Each chapter is followed by a 3-by-3 matrix containing 9 to 16 concisely worded research goals. The goals are categorized in the matrix as either low-, medium-, or high-risk and as short-, medium-, or long-term. The Action Plan also includes introductory chapters that provide an overview of the burden of liver disease in the United States and rationale for developing an Action Plan. The titles of the 16 topic chapters, the chairpersons (listed first), and the membership of the Working Groups for the topic areas are listed below.
 
Cell and Molecular Biology: Drs. Allan Wolkoff, Irwin Arias, Laura Beretta, Anne Hubbard, Mark McNiven, Michael Nathanson, and Jose Serrano
 
Cell Injury, Repair, Inflammation and Fibrosis: Drs. Gregory Gores, Mark Czaja, Scott Friedman, Jacquelyn Maher, John Lemasters, Don Rockey, and Jay Hoofnagle
 
Developmental Biology and Regeneration: Drs. Nelson Fausto, Bin Gao, Markus Grompe, Mark Kay, George Michalopoulos, Kenneth Zaret, David Shafritz, and Jose Serrano
 
Bile, Bilirubin and Cholestasis: Drs. James Boyer, Sawkat Anwer, Irwin Arias, John Chiang, David Cohen, Norman Javitt, and Jay Hoofnagle
 
Viral Hepatitis: Drs. Stanley Lemon, Harvey Alter, Francis Chisari, Jeffrey Glenn, William Mason, Charles Rice, Lesyle Johnson, and Leonard Seeff
 
HIV and Liver Disease: Drs. David Thomas, Margaret Koziel, Jules Levin, Marion Peters, Ken Sherman, Thomas Kresina, Katherine Davenny, and Fulvia Veronese
 
Fatty Liver Disease: Drs. Anna Mae Diehl, David Crabb, Joannes Hoek, Craig McClain, Arun Sanyal, and Sam Zakhari
 
Drug-Induced Liver Disease: Drs. Niel Kaplowitz, Timothy Macdonald, Sidney Nelson, Lance Pohl, Robert Roth, John Senior, Paul Watkins, and Carol Shreffler
 
Autoimmune Liver Disease: Drs. John Vierling, Nora Bergasa, Nicholas Crispe, Eric Gershwin, James Gorham, Keith Lindor, Barbara Rehermann, and Stephen James
 
Pediatric Liver Disease: Drs. Jorge Bezerra, Saul Karpen, David Perlmutter, Ron Sokol, Frederick Suchy, Tonse Raju, and Gilman Grave
 
Genetic Liver Disease: Drs. Bruce Bacon, Nancy Andrews, Herbert Bonkovsky, Joseph Bloomer, Jonathan Gitlin, Caroline Philpott, and Alan Guttmacher
 
Liver Transplantation: Drs. Jean Emond, Michael Lucey, Sue McDiarmid, Kim Olthoff, John Roberts, Hugo Rosen, and James Everhart
 
Complications of Liver Disease: Drs. Thomas Boyer, Andres Blei, Michael Fallon, Roberto Groszmann, Michael Henderson, William Lee, and Leonard Seeff
 
Liver Cancer: Drs. Adrian Di Bisceglie, Michael Abecassis, Brian Carr, Snorri Thorgeirsson, Jack Wands, and Jaye Viner
 
Gallbladder and Biliary Disease: Drs. Sum Lee, Martin Carey, Michael Kimmey, Nicholas LaRusso, Henry Pitt, and James Everhart
 
Imaging and Biotechnology: Drs. King Li, Glenn Krinsky, Jonathan Kruskal, Fred Lee, and Alan McLaughlin.
 
A total of 213 research goals were identified in the Action Plan. Several research goals from different Working Groups were similar or overlapped, and many were interactive and interdependent. The Action Plan ends with an implementation and assessment chapter and a final summary recommendations chapter. The summary recommendations chapter lists 10 benchmark research goals that encompass the broad range of liver disease research and were mentioned in multiple topic areas. These benchmark research goals will be used to measure the progress of research outlined in the Action Plan.
 
The Action Plan will be available on the web at: http://liverplan.niddk.nih.gov in December 2004, at which time hard copies can be ordered through the web site.
 
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org